Clinical Trial Update: STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea [Phase 4]

View source ↗

Summary

The STOP Trial evaluated Sandostatin LAR Depot (octreotide long-acting release) for the prevention of chemotherapy-induced diarrhea in cancer patients; the Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Diarrhea | Phase 4 | Status: COMPLETED